|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lowe KA, Chia VM, Taylor A, O'Malley C,
Kelsh M, Mohamed M, Mowat FS and Goff B: An international
assessment of ovarian cancer incidence and mortality. Gynecol
Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Durlinger AL, Gruijters MJ, Kramer P,
Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT,
Grootegoed JA and Themmen AP: Anti-Müllerian hormone attenuates the
effects of FSH on follicle development in the mouse ovary.
Endocrinology. 142:4891–4899. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Durlinger AL, Kramer P, Karels B, de Jong
FH, Uilenbroek JT, Grootegoed JA and Themmen AP: Control of
primordial follicle recruitment by anti-Müllerian hormone in the
mouse ovary. Endocrinology. 140:5789–5796. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masiakos PT, MacLaughlin DT, Maheswaran S,
Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK,
Dombkowski DM, Ha TU, et al: Human ovarian cancer, cell lines, and
primary ascites cells express the human Müllerian inhibiting
substance (MIS) type II receptor, bind, and are responsive to MIS.
Clin Cancer Res. 5:3488–3499. 1999.PubMed/NCBI
|
|
6
|
Stephen AE, Pearsall LA, Christian BP,
Donahoe PK, Vacanti JP and MacLaughlin DT: Highly purified
Müllerian inhibiting substance inhibits human ovarian cancer in
vivo. Clin Cancer Res. 8:2640–2646. 2002.PubMed/NCBI
|
|
7
|
Meirelles K, Benedict LA, Dombkowski D,
Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, MacLaughlin
DT, Donahoe PK and Wei X: Human ovarian cancer stem/progenitor
cells are stimulated by doxorubicin but inhibited by Müllerian
inhibiting substance. Proc Natl Acad Sci USA. 109:2358–2363. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei X, Dombkowski D, Meirelles K,
Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR,
Teixeira J, MacLaughlin DT and Donahoe PK: Müllerian inhibiting
substance preferentially inhibits stem/progenitors in human ovarian
cancer cell lines compared with chemotherapeutics. Proc Natl Acad
Sci USA. 107:18874–18879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szotek PP, Pieretti-Vanmarcke R, Masiakos
PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F,
Maclaughlin DT and Donahoe PK: Ovarian cancer side population
defines cells with stem cell-like characteristics and Müllerian
Inhibiting Substance responsiveness. Proc Natl Acad Sci USA.
103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pieretti-Vanmarcke R, Donahoe PK, Szotek
P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF
and MacLaughlin DT: Recombinant human Müllerian inhibiting
substance inhibits long-term growth of MIS type II
receptor-directed transgenic mouse ovarian cancers in vivo. Clin
Cancer Res. 12:1593–1598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang J, Wu YL, Chen BJ, Zhang W, Tanaka Y
and Sugiyama H: The C-kit receptor-mediated signal transduction and
tumor-related diseases. Int J Biol Sci. 9:435–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tonary AM, Macdonald EA, Faught W,
Senterman MK and Vanderhyden BC: Lack of expression of c-KIT in
ovarian cancers is associated with poor prognosis. Int J Cancer.
89:242–250. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wilczynski SP, Chen YY, Chen W, Howell SB,
Shively JE and Alberts DS: Expression and mutational analysis of
tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in
ovarian cancers. Hum Pathol. 36:242–249. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arber DA, Tamayo R and Weiss LM: Paraffin
section detection of the c-kit gene product (CD117) in human
tissues: Value in the diagnosis of mast cell disorders. Hum Pathol.
29:498–504. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu R, Wang FM, Yu L, Luo Y, Wu X, Li J,
Zhang XM, Oehninger S and Bocca S: Antimüllerian hormone regulates
stem cell factor expression in human granulosa cells. Fertil
Steril. 102:1742–1750.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Magee JA, Piskounova E and Morrison SJ:
Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer
Cell. 21:283–296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Foster R, Buckanovich RJ and Rueda BR:
Ovarian cancer stem cells: Working towards the root of stemness.
Cancer Lett. 338:147–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anttonen M, Färkkilä A, Tauriala H,
Kauppinen M, Maclaughlin DT, Unkila-Kallio L, Bützow R and
Heikinheimo M: Anti-Müllerian hormone inhibits growth of AMH type
II receptor-positive human ovarian granulosa cell tumor cells by
activating apoptosis. Lab Invest. 91:1605–1614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ha TU, Segev DL, Barbie D, Masiakos PT,
Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK
and Maheswaran S: Müllerian inhibiting substance inhibits ovarian
cell growth through an Rb-independent mechanism. J Biol Chem.
275:37101–37109. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nilsson E, Rogers N and Skinner MK:
Actions of anti-Müllerian hormone on the ovarian transcriptome to
inhibit primordial to primary follicle transition. Reproduction.
134:209–221. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Stoica G, Tasca SI, Kelly KA and
Meininger CJ: Modulation of tumor angiogenesis by stem cell factor.
Cancer Res. 60:6757–6762. 2000.PubMed/NCBI
|
|
23
|
Huang B, Lei Z, Zhang GM, Li D, Song C, Li
B, Liu Y, Yuan Y, Unkeless J, Xiong H and Feng ZH: SCF-mediated
mast cell infiltration and activation exacerbate the inflammation
and immunosuppression in tumor microenvironment. Blood.
112:1269–1279. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu J, Zhang Y, Zhao J, Yang Z, Li D,
Katirai F and Huang B: Mast cell: Insight into remodeling a tumor
microenvironment. Cancer Metastasis Rev. 30:177–184. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shaw TJ and Vanderhyden BC: AKT mediates
the pro-survival effects of KIT in ovarian cancer cells and is a
determinant of sensitivity to imatinib mesylate. Gynecol Oncol.
105:122–131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jung YS, Kim HJ, Seo SK, Choi YS, Nam EJ,
Kim S, Kim SW, Han HD, Kim JW and Kim YT: Anti-proliferative and
apoptotic activities of Müllerian inhibiting substance combined
with calcitriol in ovarian cancer cell lines. Yonsei Med J.
57:33–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Katiyar S, Jiao X, Wagner E, Lisanti MP
and Pestell RG: Somatic excision demonstrates that c-Jun induces
cellular migration and invasion through induction of stem cell
factor. Mol Cell Biol. 27:1356–1369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barbie TU, Barbie DA, MacLaughlin DT,
Maheswaran S and Donahoe PK: Mullerian Inhibiting Substance
inhibits cervical cancer cell growth via a pathway involving p130
and p107. Proc Natl Acad Sci USA. 100:15601–15606. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kano M, Sosulski AE, Zhang L, Saatcioglu
HD, Wang D, Nagykery N, Sabatini ME, Gao G, Donahoe PK and Pépin D:
AMH/MIS as a contraceptive that protects the ovarian reserve during
chemotherapy. Proc Natl Acad Sci USA. 114:E1688–E1697. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park SH, Chung YJ, Song JY, Kim SI, Pépin
D, MacLaughlin DT, Donahoe PK and Kim JH: Müllerian inhibiting
substance inhibits an ovarian cancer cell line via β-catenin
interacting protein deregulation of the Wnt signal pathway. Int J
Oncol. 50:1022–1028. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang HL, Pieretti-Vanmarcke R, Nicolaou
F, Li X, Wei X, MacLaughlin DT and Donahoe PK: Mullerian inhibiting
substance inhibits invasion and migration of epithelial cancer cell
lines. Gynecol Oncol. 120:128–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
